For us, the big headline from sanofi’s recent ‘meet the management’ day in Paris was the company’s announcement that it was reviewing the future of its European generics operation. This is as a consequence of the strategic review that has resulted in the creation...
Pharma pricing in the spotlight
The general – understandable – obsession of the generics industry with low prices tends to obscure the fact that some generics are actually quite expensive. This is particularly noticeable in the US, where pricing is effectively free and is constrained only by the need...
Midsummer M&A madness
The generic/specialty pharma M&A frenzy appears to have reached its apogee in recent days, with Mylan making an unsolicited bid for the OTC specialist, Perrigo and Teva subsequently bidding for Mylan – conditional on the Perrigo bid being dropped. Share prices have risen all...
Hikma: Up and away?
Crunch time may be approaching for the CEO of Hikma, Said Darwazah. Rumours have circulated recently that Hikma has received an approach from Mylan, an event which, if true, will pose a dilemma for the company’s Board. Hikma has, we believe, been the subject...
Retail therapy: Is it the answer for Teva?
The past year has been a good one for investment bankers, lawyers and accountants, as companies have gone on a massive M&A binge fuelled by cheap debt and highly rated equity. It has also been a generally good year for shareholders, who are benefiting...